Duke study: Adding telaprevir to Hepatitis C re-treatment regimen boosts cure rate

InsideDukeMedicine
173
2,349 views

Transcript

The interactive transcript could not be loaded.
Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Apr 12, 2010

Adding the investigational drug telaprevir to standard treatment for hepatitis C infection cures about half the patients willing to give therapy a second try. That compares to a cure rate of just 14 percent among those who were re-treated with the standard regimen, according to researchers at Duke Clinical Research Institute.

When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to